The Zambon Group hires Maxer to implement its Clinical Trial Disclosure program
The program requires Maxer to carry out the necessary activities to ensure Zambon’s compliance with the regulations in force in the European Union (EU Reg. 536/2014) and the United States (FDAAA 801 and Final Rule) to ensure the transparency of clinical studies’ results. In addition, Maxer will monitor for Zambon the evolution of UK legislation on the registration of clinical trials and the publication of their outcomes in the post-Brexit transition.
Finally, the program includes a training course on Clinical Trial Disclosure and Data Transparency for the Zambon professionals involved in these activities.